

1.8.2	Tamsulosin hydrochloride
Risk Management System	prolonged-release tablets

Part VI: Summary of the risk management plan

Summary of risk management plan for tamsulosin by Krka

This is a summary of the risk management plan (RMP) for tamsulosin by Krka. The RMP details important risks of tamsulosin by Krka, how these risks can be minimised, and how more information will be obtained about tamsulosin by Krka 's risks and uncertainties (missing information).

tamsulosin by Krka 's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how tamsulosin by Krka should be used.

Important new concerns or changes to the current ones will be included in updates of tamsulosin by Krka 's RMP.

I. The medicine and what it is used for

Tamsulosin by Krka is authorised for Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) (see SmPC for the full indication). It contains tamsulosin as the active substance and it is given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of tamsulosin by Krka together with measures to minimise such risks and the proposed studies for learning more about tamsulosin by Krka 's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;

RMS001638_1	26.03.2018 - Updated: 26.03.2018 - CONFIDENTIAL	Page 11 of 14
-------------	---	---------------

1.8.2	Tamsulosin hydrochloride
Risk Management System	prolonged-release tablets

- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of tamsulosin by Krka are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of tamsulosin by Krka. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risks	Low blood pressure when suddenly standing up (Orthostatic hypotension)
	Iris disorder during operative procedure (Intraoperative Floppy Iris Syndrome)
	Swelling of face, tongue and larynx (Angioedema)
Important potential risks	Concomitant administration with other drugs (Concomitant administration with strong CYP3A4 inhibitors)
Missing information	Administration in paediatric patients

RMS001638_1	26.03.2018 - Updated: 26.03.2018 - CONFIDENTIAL	Page 12 of 14
-------------	---	---------------

1.8.2	Tamsulosin hydrochloride
Risk Management System	prolonged-release tablets

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of <invented name>.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for tamsulosin by Krka.

RMS001638_1	26.03.2018 - Updated: 26.03.2018 - CONFIDENTIAL	Page 13 of 14
-------------	---	---------------